Bamboo Therapeutics is an early-stage biotechnology company developing therapies for rare neuromuscular and central nervous system diseases. Bamboo is currently performing IND-enabling studies and scale-up of vector manufacturing and plans to initiate a Phase 1 study in Duchenne in late 2017/ early 2018.
Research focus: Gene therapy
Status: Planned clinical trial in 2017
“The visionary support from CureDuchenne Ventures was the catalyst needed for Bamboo Therapeutics to rapidly advance its mission. Now in partnership with Pfizer, Bamboo will be able to move even faster to advance our gene therapies to clinical trials and impact the lives of Duchenne patients, regardless of their genetic mutation,” said Sheila Mikhail, Chief Executive Officer of Bamboo Therapeutics.